These findings have catalyzed further investigations into the potential use of PAPD5 small molecule inhibitors as a therapeutic strategy for PARN mutation-related disorders, such as dyskeratosis congenita (DC) [21]. The gene discussed is TENT4B; the disease is dyskeratosis congenita.